Factor Therapeutics Ltd  

(Public, ASX:FTT)   Watch this stock  
Find more results for ASX:TIS
0.0000 (0.00%)
May 24 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.04 - 0.04
52 week 0.03 - 0.08
Open 0.04
Vol / Avg. 1.88M/1.66M
Mkt cap 25.35M
P/E     -
Div/yield     -
EPS -0.05
Shares 454.32M
Beta     -
Inst. own     -
Apr 28, 2016
Tissue Therapies Ltd Extraordinary Shareholders Meeting

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -4590.39% -2132.07%
Operating margin -4577.86% -2113.22%
EBITD margin - -2097.89%
Return on average assets -192.26% -65.92%
Return on average equity -223.61% -74.33%
CDP Score - -


L 19 179 Turbot St
+61-7-33343900 (Phone)
+61-7-33343999 (Fax)

Website links


Factor Therapeutics Limited, formerly Tissue Therapies Limited, is an Australia-based biomedical technology company. The Company is engaged in developing treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. The Company is engaged in commercializing VitroGro ECM for the treatment of venous leg ulcers and diabetic foot ulcers. VitroGro is a broad spectrum healing promoter for the treatment of a range of ulcers. The Company has conducted a VITRO-CARD-1001 study using VitroGro ECM in a population of patients. VitroGro ECM binds collagen in skin, and is adsorbed onto the wound bed and not absorbed into the underlying tissues. As a consequence, the action of VitroGro ECM is localized to the wound bed. VitroGro ECM acts as a scaffold, which enables cell attachment. Tissue Therapies Europe Limited is the Company's subsidiary.

Officers and directors

Nigel Johnson Acting Chief Executive Officer
Zee Upton Chief Scientific Officer
Christian P. Behrenbruch Ph.D. Executive Director
Saskia Jo Company Secretary
Cherrell Hirst Non-Executive Director
Timothy Richard Hughes Non-Executive Director